{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"243","upperLimit":"639","value":"287"},{"groupId":"OG001","lowerLimit":"343","upperLimit":"623","value":"558"},{"groupId":"OG002","lowerLimit":"609","upperLimit":"670","value":"659"},{"groupId":"OG003","lowerLimit":"590","upperLimit":"1880","value":"1100"},{"groupId":"OG004","lowerLimit":"708","upperLimit":"2090","value":"1280"},{"groupId":"OG005","lowerLimit":"1800","upperLimit":"1800","value":"1800"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"description":"Cmax for lorlatinib in patients in cohort A1 and B1","dispersionType":"Full Range","groups":[{"description":"Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be 45 mg/m2/dose. Patients must be under 18 years of age at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG000","title":"Cohort A1 DL1"},{"description":"Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be 60 mg/m2/dose. Patients must be under 18 years of age at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG001","title":"Cohort A1 DL2"},{"description":"Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be 75 mg/m2/dose. Patients must be under 18 years of age at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG002","title":"Cohort A1 DL3"},{"description":"Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be 95 mg/m2/dose. Patients must be under 18 years of age at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG003","title":"Cohort A1 DL4"},{"description":"Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be 115 mg/m2/dose. Patients must be under 18 years of age at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG004","title":"Cohort A1 DL5"},{"description":"Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be 115 mg/m2/dose. Patients must be under 18 years of age at time of enrollment.\n\nLorlatinib: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.","id":"OG005","title":"Cohort B1 DL5"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Day 15","title":"Pharmacokinetics A1 and B1-Cmax","type":"SECONDARY","unitOfMeasure":"ng/mL"}